Recursion Announces Board TransitionSalt Lake City, UT, April 30, 2026 (GLOBE NEWSWIRE) -- Recursion (
NASDAQ: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Chris Gibson, Ph.D., will complete his current term through June 2026 and does not intend to seek re-election to the Company’s Board of Directors.
Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6Company to host public Earnings Call on May 6 at 8:00 am ET / 6:00 am MT / 1:00 pm BST
Recursion to Participate in Upcoming Investor ConferencesSalt Lake City, April 07, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in the following upcoming investor conferences:
Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech PlatformNEW YORK and SALT LAKE CITY, March 31, 2026 (GLOBE NEWSWIRE) -- Citeline, a leader in clinical solutions for the life sciences industry, today announced an expanded strategic partnership with Recursion (
NASDAQ: RXRX), a leading tech-bio company decoding biology through advanced data science and automation.
Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical OfficerSalt Lake City, UT, March 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki Goodman, M.D., will become Recursion’s Chief Medical Officer effective April 6, 2026 as David Mauro, M.D., Ph.D. transitions out of the role.
Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5thCompany to host public (L)earnings call on August 5th at 8:00 am ET / 6:00 am MT / 1:00 pm BST
Stocks Under $5 to Watch Now: LRMR, RXRX, NDRA, BTQ, CDIO Watch Now!As investors search for “stocks under $5 to buy now,” “small-cap growth stocks 2026,” “AI healthcare stocks,” “quantum computing stocks,” and “emerging Nasdaq breakout stocks,” several under-the-radar companies are drawing increased attention across financial media platforms and AI-driven discovery engines including Google AI, Grok, Meta AI, ChatGPT, Microsoft Copilot, and Perplexity AI.
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateSALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its fourth quarter and full year ending December 31, 2025.
Recursion To Be Featured in HighRes’ Lightning Talk at NVIDIA GTCSalt Lake City, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will be featured in HighRes’ Lightning Talk at the NVIDIA GTC AI Conference & Expo happening March 16-19 in San Jose. Moderated by Stacie Calad-Thomson, Business Development Lead for Healthcare and Life Sciences at NVIDIA, the talk, “AI Agents, Robotics, and Digital Twins: The Full Stack of Self-Driving Labs and Biomanufacturing,” will showcase how AI, automation, and robotics are driving the new era of drug discovery and development.
Recursion to Participate in Upcoming Investor ConferencesSalt Lake City, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences:
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing RulesSalt Lake City, Utah, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Recursion (
NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, 2026, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement restricted stock unit (RSU) awards covering 820,431 shares of its class A common stock in the aggregate to 17 new employees under Recursion's 2024 Inducement Equity Incentive Plan (the “2024 Plan”). Each award was granted as an inducement material to the employee's commencement of employment with Recursion, or a subsidiary of Recursion, pursuant to Nasdaq Listing Rule 5635(c)(4).
Recursion to Present at 44th Annual J.P. Morgan Healthcare ConferenceSalt Lake City, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President, Najat Khan, Ph.D., will present Tuesday, January 13, 10:30am PT at the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
Myseum (NASDAQ: MYSE) Ignites “Picture Party,” a New Era in Social Media on All Apple (NASDAQ: AAPL) Devices Now! more stocks inside…After years of incremental updates across major social media platforms, Myseum, Inc. (
NASDAQ: MYSE) is introducing what many see as a rare breakthrough in social media innovation with the launch of Picture Party by Myseum, a new privacy-first social networking platform designed for real-world sharing.
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 WeeksSALT LAKE CITY, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical-stage TechBio company decoding biology to radically improve lives, today announced positive Phase 1b/2 data from the ongoing TUPELO trial of REC-4881, an investigational allosteric MEK1/2 inhibitor for familial adenomatous polyposis (FAP).
Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a new clinical readout from the ongoing TUPELO Phase 1b/2 trial of REC-4881 in FAP at an upcoming company webinar. The webinar will be held on December 8, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT, and will be streamed live on Recursion’s X, LinkedIn, and YouTube accounts.
Recursion Reports Third Quarter 2025 Financial Results and Provides Business UpdateSALT LAKE CITY, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its third quarter ended September 30, 2025.
Recursion Announces CEO Transition Plan to Drive Next Phase of GrowthCo-Founder and CEO Chris Gibson to Transition to Chairman of the Board; Najat Khan to be named Chief Executive Officer and President
Recursion to Participate in Upcoming Investor ConferencesSalt Lake City, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences:
Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5thCompany to host public (L)earnings call on November 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMT
Recursion to Participate in Upcoming Investor ConferencesSalt Lake City, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences:
Recursion Reports Second Quarter 2025 Financial Results and Provides Business UpdateCompany shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7)
